Medical condition
Cardiovascular
Cardiovascular is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- icosapent ethyl (VAZKEPA) Cardiovascular system (C10)
- aliskiren (RASILEZ) Cardiovascular system (C09)
- guanfacine (INTUNIV) Cardiovascular system (C02)
- azilsartan medoxomil (EDARBI) Cardiovascular system (C09)
- plozasiran (REDEMPLO) Cardiovascular system (C10)
- dronedarone (MULTAQ) Cardiovascular system (C01)
- canagliflozin (INVOKANA) Alimentary tract and metabolism (A10)
- dopamine hydrochloride (NEOATRICON) Cardiovascular system (C01)
- bosentan (BOSENTAN APO) Cardiovascular system (C02)
- dapagliflozin (FORXIGA) Alimentary tract and metabolism (A10)
- colchicine (ARX-COLCHICINE) Musculo-skeletal system (M04)
- alirocumab (PRALUENT) Cardiovascular system (C10)
Latest Cardiovascular news
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Novo Nordisk's oral Ozempic pill receives FDA approval as the first oral GLP-1 medication for type 2 diabetes with cardiovascular risk reduction benefits.
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
The SURPASS-CVOT trial results shed light on Mounjaro's cardiovascular safety, influencing its FDA labeling and future use in diabetes management.
FDA Labeling Changes for Oral Semaglutide: Cardiovascular Risk Insights
This article explores the recent FDA labeling updates for oral Semaglutide, focusing on new insights regarding cardiovascular risks associated with its use.
FDA Approves Repatha: Key Details on Amgen's Cardiovascular Drug
Repatha, recently approved by the FDA, is a groundbreaking treatment by Amgen for cardiovascular disease, targeting high cholesterol effectively.